Join us   Log in  


Pages: 18-30

Date of Publication: 01-Jun-2023

Print Article   Download XML  Download PDF

Cost-utility analysis of adding a fourth dose at birth to the hepatitis B vaccination schedule in Côte d’Ivoire

Author: Bangaman Akani, Gary M Ginsberg, Pétronille Zengbé-Acray, Alfred Douba, Emile Allah-Kouadio

Category: Review & Research


Background. Côte d’Ivoire is considering adding a birth dose of the Hepatitis B vaccine to the current vaccination schedule (at 6, 10, and 14 weeks) in order to decrease vertical transmissions. The study aims to perform a cost-utility analysis of adding the extra Hepatitis B dose at birth.

Methods: Using a Markov model which included economic and epidemiological data, the incremental cost-effectiveness ratio (ICER) per averted disability-adjusted life years (DALYs) of adding a birth dose was calculated using a 3% discount rate. Parameter values in the model were obtained from experts’ interviews in Cote d’Ivoire, WHO Global Health Observatory data, international publications and hospital reports. Univariate sensitivity analyses were performed to account for uncertainty.

Results: In 2018, under the base case (no-vaccination) scenario, 3,940 out of the newborn cohort of 947,687 would become HBV carriers. Under the current three-dose vaccination regimen, only 947 are at risk. Adding a birth dose will reduce this by a further 104 transmissions to 843 cases. The birth dose costs $1.02 per fully immunized child, totaling $899,000 per annual birth cohort, these are exceeded by $1,627,000 savings in lifetime treatment costs. An estimated 823 DALYs will be averted due to decreased morbidity and mortality. Adopting a four-dose immunization schedule is cost-saving, cost-effective and very cost-effective when vaccine efficacy gains (relative to the current three dose-schedule) are above 1.56%, 0.35% and 0.72% respectively.

Conclusion: Since our model shows it is likely to be a cost-saving strategy, we recommend introducing the fourth dose of HBV immunization at birth in Cote d’Ivoire.

Keywords: Cost-Utility Analysis, Hepatitis B, Vaccinations




1. Chen S-T, Chang M-H. Epidemiology and Natural History of Hepatitis B in Children. In: Jonas MM, editor. Viral Hepatitis in Children. Totowa, NJ: Humana Press; 2010. p. 13–28.

2. Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. Virology. 2015; 479–480:672–86.

3. Trépo C, Chan HLY, Lok A. Hepatitis B virus infection. The Lancet. 2014; 384(9959):2053–63.

4. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study. The Lancet. 2012;380(9859):2095–128.

5. Mendy M, Peterson I, Hossin S, Peto T, Jobarteh ML, Jeng-Barry A, et al. Observational Study of Vaccine Efficacy 24 Years after the Start of Hepatitis B Vaccination in Two Gambian Villages: No Need for a Booster Dose. Rowe M, editor. PLoS ONE. 2013;8(3):e58029.

6. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. Journal of Viral Hepatitis. 2004;11(2):97–107.

7. Healy SA, Gupta S, Melvin AJ. HIV/HBV coinfection in children and antiviral therapy. Expert Rev Anti Infect Ther. 2013;11(3):251–63.

8. Lohouès-Kouacou MJ, Touré M, Hillah J, Camara B-M, N’Guessan N, Attia Y, et al. Transmission in utero of the hepatitis B virus in Ivory Coast. The case for mass vaccination. Cahiers d’études et de recherches francophones/Santé. 1999;8(6):401–4.

9. Chauvin P. The cost of not implementing routine neonates immunization programmes in HBsAg high prevalence countries. Vaccine. 2002;20(23–24):2848–50.

10. Lohouès-Kouacou M-J, Assi C, Nigué L, Biékré AR, Ouattara A, Koné S, et al. Connaissance et couverture vaccinale contre l’hépatite virale B (HVB) : étude transversale parmi les étudiants de l’université de Cocody, Côte d’Ivoire. Revue d’Épidémiologie et de Santé Publique. 2013;61(5):494–8.

11. Boa A, Douba A, N’guessan TB, Menan H, Attia A, Ouassa T, et al. A plea for introduction of hepatitis B vaccination at birth in Côte d’Ivoire. Sante publique (Vandoeuvre-les-Nancy, France). 2017;29(5):751–60.

12. Programme national de lutte contre les hépatites virales. Plan strategique de lutte contre les Hepatites virales.pdf. Ministère de la santé et de l’hygiène publique; 2015.

13. Assi C, Ouattara A, Kone S, Soro D, Allah-Kouadio E, Kouakou CG, et al. Screening for Hepatitis B and C in Occupational Settings: Cross-Sectional Study about 4268 Corporates Agents in Cote d’Ivoire. Open Journal of Gastroenterology. 2017;07(03):89–95.

14. Hall AJ, Roberston RL, Crivelli PE, Lowe Y, Inskip H, Snow SK, et al. Cost-effectiveness of hepatitis B vaccine in The Gambia. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1993;87(3):333–6.

15. Klingler C, Thoumi AI, Mrithinjayam VS. Cost-effectiveness analysis of an additional birth dose of Hepatitis B vaccine to prevent perinatal transmission in a medical setting in Mozambique. Vaccine. 2012;31(1):252–9.

16. Ginsberg GM, Shouval D. Cost-benefit analysis of a nationwide neonatal inoculation programme against hepatitis B in an area of intermediate endemicity. Journal of Epidemiology & Community Health. 1992;46(6):587–94.

17. Magoni M, Ekra KD, Aka LN, Sita KS, Kanga K. Effectiveness of hepatitis-B vaccination in Ivory Coast: the case of the Grand Bassam health district. Ann Trop Med Parasitol. 2009;103(6):519–27.

18. Assi C, Ouattara A, Allah Kouadio E, Diakite M, Koné S, Lohoues Kouacou MJ, et al. Vaccination coverage against hepatitis B and prevalence of HBsAg: A cross-sectional study involving 592 persons attending public screening in Abidjan. Clinics and research in hepatology and gastroenterology. 2011;35(6–7):506–7.

19. Shen L, Wang F, Wang F, Cui F, Zhang S, Zheng H, et al. Efficacy of yeast-derived recombinant hepatitis B vaccine after being used for 12 years in highly endemic areas in China. Vaccine. 2012;30(47):6623–7.

20. Expanded Program on Immunization Cote d’Ivoire. Multi Year Plan - EPI Cote d’Ivoire?:2016-2020. 2017.

21. WHO. WHO Prequalified Vaccines. 2016. Available from:

22. Ministère de la Santé et de l’Hygiègne Publique. Liste Nationale des Médicaments Essentiels et du Matériel Bio-Médical, version 2013. Arrêté No. 006/MSLS/CAB du 14 Janvier 2014 - Côte d’Ivoire. 2016. Available from:

23. Ministry of Public Health, Cote d’Ivoire. External review of EPI, 2015. 2016.

24. World Bank Institute. Cote d’Ivoire | Data. 2016. Available from:

25. BECEAO. Cours de référence des principales devises contre Franc CFA | BCEAO. Available from:

26. UNICEF. Vaccine Price Data HepB. Available from:

27. UNICEF. Vaccine Price Data Penta Price UNICEF. Available from:

28. Lee D, Park SM. Cost-Effectiveness Analysis of Hepatitis B Vaccination Strategies to Prevent Perinatal Transmission in North Korea: Selective Vaccination vs. Universal Vaccination. PLoS One. 2016;11(11).

29. Ekra D, Herbinger K-H, Konate S, Leblond A, Fretz C, Cilote V, et al. A non-randomized vaccine effectiveness trial of accelerated infant hepatitis B immunization schedules with a first dose at birth or age 6 weeks in Côte d’Ivoire. Vaccine. 2008 May 23;26(22):2753–61.

30. Fendrick AM, Lee JH, LaBarge C, Glick HA. Clinical and Economic Impact of a Combination Haemophilus influenzae and Hepatitis B Vaccine: Estimating Cost-effectiveness Using Decision Analysis. Arch Pediatr Adolesc Med. 1999 Feb 1;153(2):126–36.

31. Weltgesundheitsorganisation, editor. The global burden of disease: 2004 update. Geneva; 2008. 146 p.

32. Canho RD, Grosheide P, Voogd M, Huisman W, Heijtink R, Schalm S. Immunogenicity of 20 μg of recombinant DNA hepatitis B vaccine in healthy neonates: a comparison of three different vaccination schemes. Journal of medical virology. 1993;41(1):30–4.

33. Shivananda, Somani V, Srikanth BS, Mohan M, Kulkarni PS. Comparison of Two Hepatitis B Vaccines (GeneVac-B and Engerix-B) in Healthy Infants in India. Clin Vaccine Immunol. 2006;13(6):661–4.

34. Rots NY, Wijmenga-Monsuur AJ, Luytjes W, Kaaijk P, de Graaf TW, van der Zeijst BAM, et al. Hepatitis B vaccination strategies tailored to different endemicity levels: Some considerations. Vaccine. 2010;28(4):893–900.

35. Beutels P, Edmunds WJ, Antoñanzas F, De Wit GA, Evans D, Feilden R, et al. Economic Evaluation of vaccination programmes. Pharmacoeconomics. 2002;20(1):1–7.

36. Shepard DS. Cost-effectiveness in Health and Medicine. By M.R. Gold, J.E Siegel, L.B. Russell, and M.C. Weinstein (eds). New York: Oxford University Press, 1996. The Journal of Mental Health Policy and Economics. 2(2):91–2.

37. Dembélé B, Inwoley K, Diane M, Affi-Aboli R, Abisse A, Siransy B, et al. Évolution De La Prevalence Des Infections Virales Transmissibles Par Transfusion Chez Les Donneurs De Sang Du Cnts De Cote D’ivoire De 2000 A 2010. Journal de la Recherche Scientifique de l’Universite de Lome. 2014;16(1):121–32.

38. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127(5):S5–16.

39. Tu HAT, de Vries R, Woerdenbag HJ, Li SC, Le HH, van Hulst M, et al. Cost-Effectiveness Analysis of Hepatitis B Immunization in Vietnam: Application of Cost-Effectiveness Affordability Curves in Health Care Decision Making. Value in Health Regional Issues. 2012;1(1):7–14.

40. Griffiths UK, Hutton G, Pascoal EDD. The cost-effectiveness of introducing hepatitis B vaccine into infant immunization services in Mozambique. Health Policy Plan. 2005;20(1):50–9.

41. WHO. Guidelines for estimating costs of introducing new vaccines into the national immunization system. WHO; 2001. Available from:

42. Kalaivani M, Rastogi S, Kalaiselvan V, Singh GN. Adverse Reactions after Hepatitis B Vaccination: A Retrospective Analysis Using Spontaneous Reports. Journal of Young Pharmacists. 2017;9(1):55–9.

43. Velu V, Nandakumar S, Shanmugam S, Jadhav SS, Kulkarni PS, Thyagarajan SP. Comparison of three different recombinant hepatitis B vaccines: GeneVac-B, Engerix B and Shanvac B in high risk infants born to HBsAg positive mothers in India. World J Gastroenterol. 2007;13(22):3084–9.

44. WHO. Disability weights, discounting and age weighting of DALYs. WHO. 2008 Available from:

45. WHO. Metrics: Disability-Adjusted Life Year (DALY). WHO. 2013. Available from:

46. Tan-Torres Edejer T, Baltussen RM, Adam T, Hutubessy RC, Acharya A, Evans DB, et al., editors. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization; 2003. 318 p.

47. IMF. Data Mapper. 2021. Available from:

48. Sadykova DZ. Cost effectiveness analysis of universal vaccination neonatal against hepatitis B in Kazakstan. [Israel]: The Jospeh H. and Belle R. Braun Hebrew University-Hadassah School of Public Health and community Medicine Jerusalem; 2001.

49. Siddiqui MR, Gay N, Edmunds WJ, Ramsay M. Economic evaluation of infant and adolescent hepatitis B vaccination in the UK. Vaccine. 2011;29(3):466–75.

50. Moulia-Pelat J-P, Spiegel A, Excler J-L, Martin P, Roux J-F, Boutin J-P, et al. Lutte contre l’hépatite B en Polynésie française par un programme de vaccination systématique des nouveau-nés avec le vaccin Genhevac B®. Cahiers d’études et de recherches francophones/Santé. 1996;6(1):11–5.

51. Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA. Prevention of Hepatitis B Virus Transmission by Immunization: An Economic Analysis of Current Recommendations. JAMA. 1995;274(15):1201–8.

52. Torre GL, Mannocci A, Saulle R, Colamesta V, Meggiolaro A, Mipatrini D, et al. Economic evaluation of HBV vaccination: A systematic review of recent publications (2000–2013). Human Vaccines & Immunotherapeutics. 2016;12(9):2299–311.

53. Beutels P. Economic evaluations of Hepatitis B immunization: a global review of recent studies (1994-2000). Health Economics 2001. 10: 751–74.

54. WHO. Hepatitis B vaccines: WHO position paper. Weekly epidemiological record. 2009;84(40):405–20.